Abstract:Abstract Bruton’s tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies. BTK was initially shown to be defective in the primary immunodeficiency X-linked agammaglobulinemia (XLA) and is essential both for B cell development and function of mature B cells. Shortly after its discovery, BTK was placed in the signal transduction pathway downstream of the B cell antigen receptor (BCR). More recently, small-molecule inhibitors of this kinase have shown excellent anti-tumor activity, first in animal models and subsequently in clinical studies. In particular, the orally administered irreversible BTK inhibitor ibrutinib is associated with high response rates in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL), including patients with high-risk genetic lesions. Because ibrutinib is generally well tolerated and shows durable single-agent efficacy, it was rapidly approved for first-line treatment of patients with CLL in 2016. To date, evidence is accumulating for efficacy of ibrutinib in various other B cell malignancies. BTK inhibition has molecular effects beyond its classic role in BCR signaling. These involve B cell-intrinsic signaling pathways central to cellular survival, proliferation or retention in supportive lymphoid niches. Moreover, BTK functions in several myeloid cell populations representing important components of the tumor microenvironment. As a result, there is currently a considerable interest in BTK inhibition as an anti-cancer therapy, not only in B cell malignancies but also in solid tumors. Efficacy of BTK inhibition as a single agent therapy is strong, but resistance may develop, fueling the development of combination therapies that improve clinical responses. In this review, we discuss the role of BTK in B cell differentiation and B cell malignancies and highlight the importance of BTK inhibition in cancer therapy.

Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine derivatives.

Role of Bruton’s tyrosine kinase in B cells and malignancies

Targeting Bruton's tyrosine kinase in B cell malignancies

The role of Bruton's tyrosine kinase in the immune system and disease

Burgeoning Data on BTK Inactivating Mutations in Lymphomagenesis and Therapeutic Resistance

Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis

New means and challenges in the targeting of BTK

Effects of BTK Signalling in Pathogenic Microorganism Infections

Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment

Intracellular visualization of precursor capsids in phage P22 mutant infected cells.

Progression of Bruton tyrosine kinase (BTK) inhibitor in B-cell lymphoma

Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia

Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials

BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects

Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling

Insertional Transposon Mutagenesis in the Xylella fastidiosa Citrus Variegated Chlorosis Strain with Transposome

Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments

Targeting Bruton's Tyrosine Kinase in CLL

Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK

Targeting Bruton’s Tyrosine Kinase in CLL

From Mode of Action to Resistance Mechanisms